Search

Introduction/Objective. Previous investigations pointed to a notable frequency of periodontitis appearance in persons with mental disorders, but almost none of them were addressed to the periodontitis among young adults with mental disorders as a target group, which can have high public health significance. Therefore, the aim of this investigation was to estimate the prevalence of periodontitis among young adults suffering mental disorders and to determine probable risk factors for their overall periodontal health. Methods. The investigation included two groups of patients, each group having 81 participants-the study group (young adults with mental disorders) and the control group (mentally healthy young adults). The study instruments included a questionnaire (age, gender, psychoactive substances use, and maintaining oral hygiene) and community periodontal index for both groups, and the data concerning primary disease of mentally deceased patients (diagnostic category, mental disorder duration, number of hospitalizations, and psychotropic medications). Results. In terms of psychoactive substances use and maintaining oral hygiene, statistically significant differences were observed between groups in all independent variables. Young adults with mental disorders shown a high prevalence of periodontitis compared to the mentally healthy young adults. Also, gender, smoking habits, and the use of antipsychotics exhibited as possible risk factors contributing current periodontal health of young mentally deceased patients. Conclusion. This study indicates the need for more consideration for periodontal health among people with mental disorders and determination of potential models for its improvement.

This study aimed to identify risk factors for amlodipine-induced gingival enlargement, assess quality of life, and analyze gingival tissue. This cross-sectional study involved hypertensive patients on amlodipine, divided into groups with and without gingival enlargement. Assessments included sociodemographic data, clinical evaluations, and clinical parameters. Quality of life was assessed using OHIP-14 and WB-HRQoL scales. Gingival tissue samples were analyzed for oxidative status and key molecules using RT-PCR and colorimetric assays. The study included 32 patients with no significant sociodemographic differences between groups (p > 0.05). Patients with gingival enlargement had higher systolic blood pressure (139.63 ± 10.743 vs. 128.38 ± 7.249, p = 0.028) and higher OHIP-14 scores. The RT-PCR analysis showed significant differences in IL-6, TNF-α, IL-33, ST2, TGF-β1, FGF-2, CTGF, VEGF-D, and KGF expression. IL-6, TNF-α, ST2, and FGF-2 expression levels were lower in patients taking amlodipine, with and without gingival enlargement. TGF-β1 and CTGF expression levels were highest in patients with amlodipine-induced gingival enlargement. SOD activity was also highest in these patients, whereas MDA levels were higher in patients with gingival enlargement without amlodipine. Our study highlights the impact of amlodipine-induced gingival enlargement on oral health and quality of life, emphasizing fibrosis and oxidative stress, and suggests the need for integrated healthcare approaches and further research. [ABSTRACT FROM AUTHOR]